XML 17 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Cash flows from operating activities    
Net loss $ (7,917,720) $ (10,541,576)
Adjustments to reconcile net loss to cash provided by (used in) operating activities    
Stock-based compensation expense 275,688 1,425,133
Issuance of restricted stock 103,635 156,814
Depreciation, amortization and accretion 1,315,063 1,722,965
Derivative (income) (817,785) (196,148)
Amortization of prepaid research and development - related party (Note 9) 60,992
Unrealized (gain) on investment (230,936)
Compensation through issuance of stock 509,996
Issuance of warrants to initial investors 596,434
Adjustments to reconcile net loss to net cash used in operating activities:    
(Increase) in accounts receivable (849,397) (419,966)
(Increase) decrease in inventory (67,585) 85,741
(Increase) in prepaid expenses and other (454,595) (221,015)
Increase (decrease) in accounts payable and other 1,124,558 (195,836)
(Decrease) in accrued liabilities (524,905) (238,395)
Increase (decrease) in accrued compensation 497,586 (681,432)
(Decrease) in deferred rent (3,337) (1,350)
Net cash used in operating activities (7,318,794) (8,168,579)
Cash flows used in investing activities    
Purchases of property and equipment (12,195) (44,876)
Installment payment for Natesto asset (2,000,000)
Installment payment for Primsol asset (750,000)
Net cash used in investing activities (12,195) (2,794,876)
Cash flows from financing activities    
Issuance of preferred, common stock and warrants 11,839,995
Issuance costs related to preferred, common stock and warrants (1,402,831)
Issuance of common stock to Lincoln Park Capital 631,481
Costs related to sale of common stock (24,247)
Registered offering of common stock and warrants 8,602,500
Registered offering costs (997,865)
Over-allotment warrants purchased by placement agents 2,852
Net cash provided by financing activities 10,437,164 8,214,721
Net change in cash, cash equivalents and restricted cash 3,106,175 (2,748,734)
Cash, cash equivalents and restricted cash at beginning of period 877,542 8,054,190
Cash, cash equivalents and restricted cash at end of period 3,983,717 5,305,456
Non-cash transactions:    
Warrants issued to investors and underwriters (see Note 5) 4,117,997
Revenue share payment to Jazz 7,385
Earn-out payment to Nuelle Shareholders 250,000
Fixed assets included in accounts payable 62,512 61,241
Warrants issued in connection with the equity financing to the placement agents $ 292,630